our services
Able Biolabs’ capabilities encompass the full range of research needs.
We have non-GLP in-house facilities and work
with trusted partners to support GLP activities. Whether you’re developing a new drug or a consumer product, we generate the necessary preclinical and clinical scientific validation to support your needs.
Our team of PhD-level scientists can perform previously validated protocols or work with you to develop and refine models based on both parties’ shared expertise. Our process is transparent and collaborative in order to best facilitate the progress of your research program.
In vitro and
ex vivo models
We leverage traditional cell-based models as well as ex vivo approaches such as air-liquid interface and organoids to support your initial proof of concept work
• Traditional cell culture models
• Primary human cells
• Organoids
• Air-liquid interface (ALI)
in vivo
Drug assets can be tested for therapeutic or preventive activity using any route of administration.
• Exposure/induced models
• Humanized animal models
• Germ-free
Our team has particular expertise in chronic
and infectious respiratory disease models:
• Chronic disease – COPD, BPD, IPF, asthma, acute lung injury, PAH, CF
• Infectious disease – COVID, RSV, viral infection, fungal infection
CUSTOM MODELS
For models that are not “out of the box,” we offer support in developing and validating protocols. Contact us to start a discussion about your specific needs.
• Rare disease
• Transgenic animal models
CLINICAL TRIALS
Able Biolabs supports randomized controlled clinical trials and consumer feedback studies for CPG brands. Trials are virtual and supported by a fully integrated digital platform that participants use on their mobile devices.
• Fast recruitment times
• Fully virtual decentralized trials
• Integration with wearable devices for data capture
• Integration with Quest Diagnostics
